ReviewFrontiers in bioengineering and biotechnology2020
Immobilization of Growth Factors for Cell Therapy Manufacturing.
Review in Frontiers in bioengineering and biotechnology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 29 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed, 52 citations in OpenAlex.
- Supramolecular engineering of fibrinogen into a fibrin matrix with enhanced bioactive properties.Bioactive materials · 2027Article
- Towards Cost-Effective and Sustainable Media Formulations for Terrestrial and Aquatic Cellular Agriculture.Foods (Basel, Switzerland) · 2026Review
- Article
- A Heparin-Functionalized Scaffold with HB-EGF Immobilization for Tissue Engineering.Advanced healthcare materials · 2026Article
- Glycosaminoglycan-Inspired Polymer Brushes Promote Human Mesenchymal Stem Cell Proliferation While Retaining Trilineage Differentiation Potential.ACS applied materials & interfaces · 2026Article
- Optimizing neurogenic differentiation of dental stem cells: a critical review of induction strategies and functional validation.Frontiers in dental medicine · 2026Review
- Transient expression of human interleukin-15 inPlant biotechnology (Tokyo, Japan) · 2025Article
- Emerging Approaches to Mitigate Neural Cell Degeneration with Nanoparticles-Enhanced Polyelectrolyte Systems.Membranes · 2025Review
- Enhancing the Potency of Growth Factor-Mimicking Peptides via Cross-Presentation With Integrin Ligands.Journal of biomedical materials research. Part A · 2025Article
- Hydrogels for Peripheral Nerve Repair: Emerging Materials and Therapeutic Applications.Gels (Basel, Switzerland) · 2025Review
- Material surface conjugated with fibroblast growth factor-2 for pluripotent stem cell culture and differentiation.Regenerative biomaterials · 2025Article
- Cell Adhesion and Local Cytokine Control on Protein-Functionalized PNIPAM-co-AAc Hydrogel Microcarriers.Small (Weinheim an der Bergstrasse, Germany) · 2025Article
- Alginate-gelatin hydrogel supplemented with platelet concentrates can be used as bioinks for scaffold printing.Asian biomedicine : research, reviews and news · 2023Article
- Mimicking Molecular Pathways in the Design of Smart Hydrogels for the Design of Vascularized Engineered Tissues.International journal of molecular sciences · 2023Review
- The Diamond Concept Enigma: Recent Trends of Its Implementation in Cross-linked Chitosan-Based Scaffolds for Bone Tissue Engineering.ACS applied bio materials · 2023Review
- Optimizing Delivery of Therapeutic Growth Factors for Bone and Cartilage Regeneration.Gels (Basel, Switzerland) · 2023Review
- Article
- Enhancement of keratinocyte growth factor potential in inducing adipose-derived stem cells differentiation into keratinocytes by collagen-targeting.Journal of cellular and molecular medicine · 2022Article
- Bioengineering Approaches for Delivering Growth Factors: A Focus on Bone and Cartilage Regeneration.Bioengineering (Basel, Switzerland) · 2022Review
- Engineering Extracellular Microenvironment for Tissue Regeneration.Bioengineering (Basel, Switzerland) · 2022Review
Corrections and comments
- Erratum issued
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cell therapy products exhibit great therapeutic potential but come with a deterring price tag partly caused by their costly manufacturing processes. The development of strategies that lead to cost-effective cell production is key to expand the reach of cell therapies. Growth factors are critical culture media components required for the maintenance and differentiation of cells in culture and are widely employed in cell therapy manufacturing. However, they are expensive, and their common use in soluble form is often associated with decreased stability and bioactivity. Immobilization has emerged as a possible strategy to optimize growth factor use in cell culture. To date, several immobilization techniques have been reported for attaching growth factors onto a variety of biomaterials, but these have been focused on tissue engineering. This review briefly summarizes the current landscape of cell therapy manufacturing, before describing the types of chemistry that can be used to immobilize growth factors for cell culture. Emphasis is placed to identify strategies that could reduce growth factor usage and enhance bioactivity. Finally, we describe a case study for stem cell factor.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.